Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sonus Pharmaceuticals has initiated a phase I clinical study for its second oncology product candidate, Tocosol Camptothecin.
Subscribe to our email newsletter
Formulated with the company’s proprietary vitamin E-based Tocosol technology, Tocosol Camptothecin is a new chemical entity that is a conjugate of SN-38. SN-38 is the active ingredient in irinotecan, a commercially available camptothecin analog.
Preclinical data suggest that Tocosol Camptothecin may be more efficacious and better tolerated than irinotecan.
The phase I study of Tocosol will investigate the safety profile of Tocosol Camptothecin at different doses in order to determine the maximum tolerated dose in humans. The phase I study is also designed to observe anti-tumor effects of Tocosol Camptothecin as well as to characterize the pharmacokinetics of the drug.
“This promising compound may have the ability to improve outcomes in patients treated with camptothecin-based drugs,” said Howard Burris III, director of drug development at SCRI.